Please login to the form below

What does the COVID-19 vaccine mean for the future of R&D?

Amid a pandemic, time is a luxury the world cannot afford. The last 12 months have contradicted what we once thought about the speed of progressing scientific research. Here Shannon Lacombe explores the factors that have contributed to the unprecedented speed of vaccine development from early-stage research to mass public rollout. She also looks at what precedent this has set for the future of research and development timelines and the assumptions and status quo that will now be challenged as a result.

By Shannon Lacombe, Senior Consultant, Hanover Health

Before COVID-19, it took an average of about ten years to develop a completely new vaccine, with the process never before achieved in less than five years. Given scientific research progresses so slowly under normal circumstances, how have the COVID-19 vaccines been developed so quickly and what does this mean for the future of vaccine R&D?

Amid a pandemic, time is a luxury the world cannot afford. And whilst a lot is still left to play out, the COVID-19 pandemic will be an example of what science can achieve when the world’s resources and time are focused on achieving one thing.

Timing is everything… 

The pressure to develop a vaccine against the COVID-19 virus, SARS-CoV-2, has coincided with an unprecedented explosion of fundamental science and innovation in areas such as genomics and molecular biology, that is supporting a new era in vaccine development.

Advances in genomic sequencing meant that researchers were able to uncover the RNA sequence of SARS-CoV-2 in January 2020 – roughly ten days after the first reported cases in China. Furthermore, much of the technology that underpins modern vaccine progress, such as the development of the molecular components of vaccines and manufacturing facilities with capacity to develop vaccines at scale, we didn’t have twenty years ago.

In addition to the concurrence with a scientific awakening, are our learnings from pandemics and epidemics experienced before. Over the past fifteen to twenty years, the scientific community has had to respond urgently to solve major public health crises. In 2009, the development of an H1N1 vaccine utilised existing flu vaccine technology. This showed the potential of “platform technologies” which involve slotting genetic material from a novel pathogen or virus into a tried and tested existing machinery. The use of platform vaccine technologies means that multiple vaccines against different diseases can be produced from a single proven method, typically meaning they can be developed rapidly and with a greater understanding of the safety profile from the offset.

Since then, companies and cross-sector collaborations have been investing significantly in such approaches. The Coalition for Epidemic Preparedness Innovation (CEPI), for example, has been supporting the development of vaccines against five emerging pathogens on the World Health Organization priority list, since its genesis in 2017. CEPI also supports the development of platform technologies to prepare for “Disease X” – any newly emerging and potentially epidemic disease, such as COVID-19.

Both the Oxford/AstraZeneca and Pfizer/BioNTech vaccines were developed using platform technologies which didn’t exist 20 years ago, allowing these vaccines to be developed much faster. The use of this technology should also be reassuring, should the current vaccines prove to be less effective against new COVID-19 variants, as these can be adapted rather than needing to start the development process from scratch.

…And money helps

Vaccine R&D is hugely costly.

Very soon into its life, the pandemic became a major political topic and the cost of not addressing it began to far outweigh the cost of finding a solution.  Public and private resources have been poured into COVID-19 vaccine development. Not only does this help to mitigate the initial cost burden associated with R&D, it also reduces some of the usual financial risk facing pharmaceutical companies. What’s more is with the level of demand and the guaranteed market, with governments pre-buying vaccines, companies were able to take greater risks with early-stage research. In normal circumstances, companies will carefully consider the demand and market and take strategic decisions at each step in the scientific process to consider the best commercial route. Collaborative funding pushed many of the usual hurdles aside.

In the United States, Operation Warp Speed (OWS) is working with multiple organisations, to develop, manufacture and distribute 300 million vaccine doses in 2021. The European Commission and the UK Government Vaccine Taskforce have also been significant contributors to a wide variety of vaccine projects.

Through an exceptional effort, clinical trial phases which are normally carried out in sequence, were overlapped and also conducted in parallel with vaccine manufacturing. Advances in data-recording technology and social media coupled with the wide-ranging inclusion criteria meant that recruiting trial participants was relatively straightforward, as was the regulatory process where organisations, such as the European Medicines Agency (EMA) introduced “rolling reviews”, to monitor data as and when it was produced.

Quoted in a recent article on the COVID symptom study app, Professor Peter Openshaw from Imperial College London said, “There’s been so much money poured into the process that it’s like the milk float has a police escort and all the traffic lights are on green. It doesn’t mean to say that the route that has been taken is any different.”

The power of partnerships…

Clearly, rapid vaccine R&D requires extraordinary cross-industry and sector collaboration. The pharmaceutical industry should reflect on the events of this past year, and consider how to shape its partnerships for success in the future. The pandemic should testify to the power of close dialogue with regulators and new models of peer-to-peer collaboration.

Vaccines have never before been so centre stage. The public have seen what science can achieve when the world’s resources and time are focused on achieving one thing. This raises the question of whether we will ever be able to return to ten year timeframes for developing new vaccines. Ultimately, the speed of such scientific success is not the result of one magic bullet, but the culmination of a number of factors that have all played a part. Companies will now be considering and experimenting with ways to accelerate R&D and the role of public interest. With increased public scrutiny and reinvigorated political will for progressing science, there will be a role for a strategic and connected approach across communications, policy, and R&D to reflect on how much has changed, and on what new factors should shape decisions and actions in the years ahead.

3rd February 2021


Company Details

Hanover Communications

+44 (0)20 7400 4480

Contact Website

Riverside House
Southwark Bridge House
United Kingdom

Latest content on this profile

Femtech: Transforming the future of women's healthcare
Femtech is potentially the most important development in health care right now. Women's health has been under-researched and overlooked for successive generations - it's time that government and industry get ready to deliver.
Hanover Communications
VPAS: The importance of making the right arguments, even in challenging times
With key workers’ strikes, inflation, and immense pressure on public services, arguing for a more generous pricing settlement for the pharmaceuticals industry could not be tougher. Read our Health Director James Mole’s thoughts on the support needed to protect the UK life sciences’ ambitions, despite the challenging backdrop.
Hanover Communications
Putting prevention at the heart of the future of the NHS
Prioritising the prevention of cardiovascular disease (CVD) should be at the heart of plans to safeguard the long-term sustainability of the NHS. Unfortunately, action in this area has to date not matched ambition, putting thousands of patients’ lives – and the future of the health system – at risk.
Hanover Communications
Action on Anti-microbial resistance: Will the UK rise to the challenge
Timely and effective antimicrobials are the cornerstone of our healthcare systems, providing life-saving treatment and supporting vital services like routine operations, transplants and cancer treatment. We are three years into the UK Government’s 20-Year Vision for Antimicrobial Resistance (AMR), and the Department of Health and Social Care recently launched a consultation for the next iteration of the AMR National Action Plan (2024-2029). However, latest figures show that AMR is still on the rise. Is UK policy ambitious enough to drive innovation in AMR, and is the Government on track to contain, control and mitigate AMR by 2040?
Hanover Communications
Winter and workforce woes: challenges facing the new Secretary of State for Health and Social Care
For the third time this year, the NHS and social care has a new Secretary of State. The appointment must now signal stability following a period of political turbulence, as we head into what health leaders are describing as the toughest winter to date. Backlogs, delayed discharges, ambulance and A&E pressures, and crumbling NHS estates will remain top of Steve Barclay’s priority list in the coming weeks and months ahead. However, he will also need to address the longstanding workforce issues that hold back both the NHS and social care sector. Only dealing with these structural challenges will ensure the health and care system is operationally fit for winters to come.
Hanover Communications
A new 10-year cancer plan: Will the government be able to deliver what the sector needs?
The Truss Government has committ­ed to developing a new 10-year cancer plan. But set against the backdrop of the Secretary of States priorities, what real value can the sector expect a new cancer plan to deliver? What questions need addressing to drive impactful change for patients? Will there be funding available to support the transformation?  We will explore the state of play of cancer care in England and assess the main priorities, including how they align with wider NHS challenges. We will set out the difficult choices that a new plan must confront to enable prioritisation of this complex disease area and consider the balance between taking action to impact patients now versus initiatives to benefit patients of the future.
Hanover Communications